Development of Engineered T Cells Expressing a Chimeric CD16-CD3  Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia

Published 2016 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Development of Engineered T Cells Expressing a Chimeric CD16-CD3  Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia
Authors
Keywords
-
Journal
CLINICAL CANCER RESEARCH
Volume 22, Issue 17, Pages 4405-4416
Publisher
American Association for Cancer Research (AACR)
Online
2016-04-19
DOI
10.1158/1078-0432.ccr-15-2714

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.